KURA
NASDAQ HealthcareKura Oncology, Inc. - Common Stock
Biotechnology
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
๐ Market Data
| Price | $11.28 |
|---|---|
| Volume | 2,011,091 |
| Market Cap | 1.00B |
| Beta | 0.380 |
| RSI (14-Day) | 75.5 Overbought |
| 200-Day MA | $9.64 |
| 50-Day MA | $10.20 |
| 52-Week High | $12.49 |
| 52-Week Low | $6.95 |
| Forward P/E | -4.90 |
| Price / Book | 9.28 |
๐ฏ Investment Strategy Scores
KURA scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (90/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Moon Shot (9/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find KURA in your text
Paste any article, transcript, or post โ the tool will extract KURA and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-08-17.